

Title (en)
INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF

Title (de)
INHIBITOREN VON MIT POLYNUKLEOTIDWIEDERHOLUNGEN ASSOZIIERTEN RNA-FOCI UND VERWENDUNGEN DAVON

Title (fr)
INHIBITEURS D'AGRÉGATS D'ARN ASSOCIÉS À LA RÉPÉTITION DE POLYNUCLÉOTIDES ET LEURS UTILISATIONS

Publication
EP 3049393 A4 20170621 (EN)

Application
EP 13894694 A 20130925

Priority
CA 2013050730 W 20130925

Abstract (en)
[origin: WO2015042685A1] Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhibition of the formation and accumulation such RNA foci, as well as for the treatment of polynucleotide repeat disorders (e.g., trinucleotide repeat disorders), such as myotonic dystrophy (e.g., DM1). Such compounds include compounds of formula 1, 1a, 1b, 2, 2a and (3) described herein.

IPC 8 full level
C07D 231/14 (2006.01); **A61K 31/18** (2006.01); **A61K 31/352** (2006.01); **A61K 31/36** (2006.01); **A61K 31/4155** (2006.01); **A61K 31/4406** (2006.01); **A61K 31/4453** (2006.01); **A61K 31/496** (2006.01); **A61K 31/5375** (2006.01); **A61P 21/00** (2006.01); **C07C 311/46** (2006.01); **C07D 213/82** (2006.01); **C07D 217/08** (2006.01); **C07D 265/30** (2006.01); **C07D 295/26** (2006.01); **C07D 311/84** (2006.01); **C07D 317/68** (2006.01); **C07D 409/12** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP)
A61K 31/18 (2013.01); **A61K 31/352** (2013.01); **A61K 31/36** (2013.01); **A61K 31/415** (2013.01); **A61K 31/4155** (2013.01); **A61K 31/4406** (2013.01); **A61K 31/451** (2013.01); **A61K 31/454** (2013.01); **A61K 31/496** (2013.01); **A61K 31/5375** (2013.01); **A61K 31/5377** (2013.01); **A61K 31/63** (2013.01); **A61P 21/00** (2017.12); **C07C 311/46** (2013.01); **C07D 231/14** (2013.01); **C07D 409/12** (2013.01); **G01N 33/502** (2013.01); **C07C 2601/08** (2017.04); **C07C 2603/74** (2017.04)

Citation (search report)
• [XII] WO 2006002421 A2 20060105 - VERTEX PHARMA [US], et al
• [X] WO 03037274 A2 20030508 - ICAGEN INC [US], et al
• [I] WO 2008011476 A2 20080124 - GEN HOSPITAL CORP [US], et al
• [T] KHANFAR MOHAMMAD A ET AL: "Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 76, 6 February 2014 (2014-02-06), pages 414 - 426, XP028633478, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2014.02.003
• See references of WO 2015042685A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2015042685 A1 20150402; CA 2923503 A1 20150402; EP 3049393 A1 20160803; EP 3049393 A4 20170621

DOCDB simple family (application)
CA 2013050730 W 20130925; CA 2923503 A 20130925; EP 13894694 A 20130925